6  Before treating with erythropoiesis-stimulating agents, it’s important to investigate and rule out underlying treatable conditions, such as iron or vitamin deficiencies
6  What is the major cause of death for people with chronic kidney disease?
4  When you learn about a new drug in the pipeline, do you:
94  If tolvaptan for ADPKD was approved for use but not deemed to be cost-effective, would you still prescribe it to your patients?
176  Would you use a subsequent entry biologic erythropoietin in place of an originator drug when treating anemia?